- Email: [email protected]
Efficacy of Rituximab Mono-Therapy on Bronchial-Associated Lymphoid Tissue Lymphoma
Annals of Oncology 25 (Supplement 5): v75–v109, 2014 doi:10.1093/annonc/mdu436.100
Poster Session (Poster presentations categorized by each organ) P2
21
2
Ikue Okamura1, Hisao Imai2, Kazuto Ogura1, Atsushi Isoda3, Keichiro Mihara4, Takashi Ikeda1 1 Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center 2 Division of Thoracic Oncology, Shizuoka Cancer Center 3 Department of Hematology, NHO Nishigunma National Hospital 4 Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University
abstracts
Introduction: Bronchial-associated lymphoid tissue (BALT) lymphoma is a primary pulmonary B-cell lymphoma. It has an indolent course, with a survival rate of 80% to 95% for 5 years from diagnosis, but progression-free survival is relatively short. There is
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v97/2240351 by guest on 24 October 2019
EFFICACY OF RITUXIMAB MONO-THERAPY ON BRONCHIAL-ASSOCIATED LYMPHOID TISSUE LYMPHOMA
no consensus on the standard initial treatment for BALT lymphoma. The purpose of this study is to assess the optimal treatment for this rare disease. Patients: We retrospectively studied a total of 8 cases with biopsy-proven BALT lymphoma from August 2003 to March 2013 in 3 institutions. The original study was carried out by Shizuoka Cancer Center. This study includes Shizuoka Cancer Center, Nishigunma National Hospital and Hiroshima University Hospital. Methods: There were 4 men and 4 women, median age 59 years (range, 32–74 years); Five were asymptomatic at diagnosis. In the remaining 3 cases, non-specific pulmonary complaints such as sputum and dyspnea were observed. Five patients had only unilateral lung disease, 3 had bilateral locations and 2 had bone marrow involvement. All patients treated primarily with rituximab mono-therapy, intravenous rituximab 375 mg/m2 per day was added for 4 to 8 cycles. Five achieved complete remission (CR) and 1 had partial response (PR), while the remaining 2 had stable disease (SD). One SD patient, who had dyspnea, received chemotherapy with mitoxantrone plus cladribine and rituximab obtained PR. The remaining non-CR patients had no symptoms, so we decided to observe then with no therapy. All 8 patients were alive during the median follow-up period of 58 months (range, 2-124 months). Results: BALT lymphoma has an indolent nature with favorable prognosis. Intensive chemotherapy may not be necessary. Rituximab mono-therapy may be enough treatment to control symptoms. We will continue to follow these 8 cases and will report on any new additional cases.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Poster Session (Poster presentations categorized by each organ) P2
21
2
Ikue Okamura1, Hisao Imai2, Kazuto Ogura1, Atsushi Isoda3, Keichiro Mihara4, Takashi Ikeda1 1 Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center 2 Division of Thoracic Oncology, Shizuoka Cancer Center 3 Department of Hematology, NHO Nishigunma National Hospital 4 Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University
abstracts
Introduction: Bronchial-associated lymphoid tissue (BALT) lymphoma is a primary pulmonary B-cell lymphoma. It has an indolent course, with a survival rate of 80% to 95% for 5 years from diagnosis, but progression-free survival is relatively short. There is
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v97/2240351 by guest on 24 October 2019
EFFICACY OF RITUXIMAB MONO-THERAPY ON BRONCHIAL-ASSOCIATED LYMPHOID TISSUE LYMPHOMA
no consensus on the standard initial treatment for BALT lymphoma. The purpose of this study is to assess the optimal treatment for this rare disease. Patients: We retrospectively studied a total of 8 cases with biopsy-proven BALT lymphoma from August 2003 to March 2013 in 3 institutions. The original study was carried out by Shizuoka Cancer Center. This study includes Shizuoka Cancer Center, Nishigunma National Hospital and Hiroshima University Hospital. Methods: There were 4 men and 4 women, median age 59 years (range, 32–74 years); Five were asymptomatic at diagnosis. In the remaining 3 cases, non-specific pulmonary complaints such as sputum and dyspnea were observed. Five patients had only unilateral lung disease, 3 had bilateral locations and 2 had bone marrow involvement. All patients treated primarily with rituximab mono-therapy, intravenous rituximab 375 mg/m2 per day was added for 4 to 8 cycles. Five achieved complete remission (CR) and 1 had partial response (PR), while the remaining 2 had stable disease (SD). One SD patient, who had dyspnea, received chemotherapy with mitoxantrone plus cladribine and rituximab obtained PR. The remaining non-CR patients had no symptoms, so we decided to observe then with no therapy. All 8 patients were alive during the median follow-up period of 58 months (range, 2-124 months). Results: BALT lymphoma has an indolent nature with favorable prognosis. Intensive chemotherapy may not be necessary. Rituximab mono-therapy may be enough treatment to control symptoms. We will continue to follow these 8 cases and will report on any new additional cases.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].